Prof. Dr. Vignali Joins Secarna Pharmaceuticals' Scientific Board

Secarna Pharmaceuticals has announced the addition of Prof. Dr. Dario A.A. Vignali to its Scientific Advisory Board. Prof. Vignali is recognized for his extensive research in cancer immune regulation and the immunosuppressive tumor microenvironment. His contributions include discoveries such as PD-1 and IL-35, positioning him as an expert in the field of immuno-oncology.

Bringing experience in targeting NRP1, the focus of Secarna's SECN-15 program, Prof. Vignali's role is expected to enhance the development of potential cancer treatments. He joins existing board members, Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both noted figures in cancer research. Secarna looks forward to leveraging his expertise in advancing their antisense oligonucleotide program, aiming to develop new therapeutics for cancer treatment.